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ABSTRACT: Facilitated anion transport potentially represents a powerful tool to modulate various cellular functions. However, 
research into the biological effects of small molecule anionophores are still at an early stage. Here we have used two potent aniono-
phore molecules inspired in the structure of marine metabolites tambjamines to gain insight into the effect induced by these com-
pounds at the cellular level. We show how active anionophores, capable of facilitating the transmembrane transport of chloride and 
bicarbonate in model phospholipid liposomes, induce acidification of the cytosol and hyperpolarization of plasma cell membranes. 
We demonstrate how this combined effect can be used against cancer stem cells (CSCs). Hyperpolarization of cell membrane in-
duces cell differentiation and loss of stemness of CSCs leading to effective elimination of this cancer cell subpopulation. 
INTRODUCTION 
Transmembrane ion channels and pumps are sophisticated 
cellular machineries involved in many biological processes. 
As such, ion channels constitute one of the main drug targets 
in medicinal chemistry. An estimated 13% of currently ap-
proved drugs have ion channels as their main therapeutic 
target, being used for the treatment of a variety of disease 
conditions.1 The most successful strategy to modulate trans-
membrane ion flux is to use small molecules activators or 
blockers of endogenous proteins. Nevertheless, there is an 
intense interest in designing artificial ion channels and iono-
phores.2,3 In particular, cation selective ionophores are widely 
used as antibiotics and research tools. In the last few years, the 
development of small molecules capable of facilitating the 
transmembrane transport of anions has emerged as an active 
research field.4-6 A number of molecules inspired by naturally 
occurring anionophores such as prodiginines or by synthetic 
molecules containing amide, (thio)urea, or (thio)squaramide 
hydrogen bond donors have been characterized as efficient 
anion transporters.7-10 The potential biological applications of 
these compounds have been less explored. In a seminal work, 
Magda, Sessler et. al. linked the anionophoric activity of pro-
digiosin-like molecules with their anticancer activity.11 Further 
work by different research groups delineated relationships 
between the transmembrane transport of anions and the cyto-
toxicity induced by some of these compounds.12 Very recently, 
Gale, Sessler, Shin and coworkers have demonstrated how 
diamide-strapped calix[4]pyrroles induced apoptosis via a 
caspase-dependent pathway as a result of the facilitated sodi-
um and chloride influx promoted by these derivatives.13 
Potentially, facilitated transmembrane transport of chloride 
and bicarbonate (the most abundant anions in biological envi-
ronments) could impact on cellular ion homeostasis, pH levels 
and membrane potentials. These are key parameters for cell 
survival and there is a growing body of evidence showing their 
relationships with cancer development and progression.14 
Dysregulated pH has been recognized as a hallmark of cancer. 




Figure 1. Studied compounds. (a) molecular structures of compounds 1 - 3. (b) X-Ray structures of compounds 1 and 2 as hydrochloride 
salts. 
differentiated cells, with intracellular pH (pHi) higher than 
extracellular pH.15 This reversed gradient is regulated by ion 
channels and pumps, and facilitates cancer progression being 
permissive for some of the acquired characteristics of cancer 
cells, such as sustained proliferative signalling or resistance to 
cell death.16 Membrane potential (Vm) also play key roles in 
cancer development and cell differentiation.17 Non-
proliferating, terminally differentiated somatic cells, such as 
muscle cells and neurons, are characterized by their hyperpo-
larized Vm, whereas proliferative cells, especially rapidly 
proliferating tumour cells, displayed depolarized Vm. Interest-
ingly, cancer stem cells (CSCs), a tumor cell subpopulation 
that exhibits tumor-initiating capacity, self-renewal in serial 
transplantation assays and contributes to acquired chemother-
apy resistance in cancer,18 need to maintain a depolarized Vm 
in order to preserve their stemness capacities.19,20 Therefore, 
pH modulation to avoid cancer cells acquired advantages, as 
well as, suppression of stemness properties through the modu-
lation of plasma membrane potential might be promising new 
therapeutic strategies for cancer treatment. High-throughput 
screening of selective inhibitors of CSC growth and survival 
have identified the potassium ionophore salinomycin as a 
promising drug candidate, although its mechanism of action is 
unclear.21 The potential of a synthetic chloride channel to 
regulate cell membrane potential has also been reported.22 
Here we report the biological activity of transmembrane 
anion transporters inspired in the structure of marine metabo-
lites tambjamines. We demonstrate how these molecules in-
duce pHi acidification and cytotoxicity related to their anion 
transport abilities. We also show how the facilitated transport 
activity triggers plasma membrane hyperpolarization leading 
to cancer stem cell differentiation and effective elimination of 
this cell population. 
RESULTS AND DISCUSSION 
Synthesis and anion transport through lipid bilayers. 
Compounds 1-3 (Chart 1) were selected for this study. These 
compounds are inspired in the structure of marine secondary 
metabolites tambjamines.23 They are readily prepared by acid 
catalyzed condensation of 5-(1H-indol-2-yl)-3-methoxy-1H-
pyrrole-2-carbaldehyde and the appropriate amine. These 
compounds are isolated as stable yellow-orange solids in good 
yields as hydrochloride salts and fully characterized (see sup-
porting information for details). The spectroscopic data evi-
denced the strong hydrogen bond interaction between these 
compounds and the chloride anion. These interactions are also 
evident in the solid state structures of compounds 1 and 2 
(Chart 1). The two heterocycles and the enamine moiety are 
essentially coplanar. A chloride anion is found interacting with 
the pyrrole and enamine N-H groups whereas the indole moie-
ty is found rotated 180 and interacting with a second chloride 
anion. A conformational analysis of these molecules both in 
solution and computationally is provided in the supplementary 
information. In their preferred conformation these molecules 
bind the anion through the hydrogen bond cleft involving the 
three N-H groups of the molecule. 
The chloride anion binding ability of 1 and 2 was explored 
by means of 1H NMR titration experiments using perchlorate 
salts of these derivatives and tetrabutylammoniun chloride in 
DMSO-d6. Under these conditions chloride readily replace the 
less coordinating perchlorate anion and an association con-
stants could be calculated at 3301 and 3778 M-1 for 1.HClO4 
and 2.HClO4 respectively. Treatment of DMSO-d6 solutions of 
1.HClO4 and 2.HClO4 with tetraethylammonium bicarbonate 
resulted in deprotonation of the compounds. Lack of solubility 
prevented the study of these processes in pure water. Nevethe-
less, the apparent pKa values of 1 and 2 were calculated in 
DMSO:water 1:1 mixtures at 9.64 and 9.62. This result as well 
as computational studies suggested that deprotonation is not 
likely to occur under physiological conditions (See supple-
mentary Figures S89-S92). On the other hand, in their neutral 
form, these derivatives are also able to bind anions under these 
conditions albeit with lower affinity (See supplementary Fig-
ures S49-S53). 
The anion transport properties of 1-3 were assayed in 1-
palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) 
vesicles using a chloride selective electrode to evaluate the 
chloride efflux promoted by these compounds. Thus, lipo-
somes loaded with NaCl were suspended in an isotonic, chlo-
ride free external medium. Chloride release promoted by 1-3 
 
was monitored over time and at the end of the experiment the 
vesicles were lysed by the addition of detergent, being the 
final electrode reading used as 100% release of chloride. Re-
peating these assays in the presence of variable amounts of 
compound allowed Hill analyses and calculation of EC50 val-
ues (the concentration of carrier needed to achieve the release 
of 50% of encapsulated chloride) for comparative purposes 
(Table 1). Compounds 1 and 2 proved to be extremely active 
transmembrane transporters, whereas compound 3 displayed 
modest activity as anion carrier. This difference in transmem-
brane transport activity is likely due to the significantly lower 
calculated lipophilicity of 3 with respect to 1 and 2 (See table 
S3). The key role of lipophilicity in the design of effective 
anion transporters has been studied in several families of com-
pounds including tambjamine analogs.24,25  
Table 1. Transport activities for compounds 1-3.  
Compound EC50 NO3ˉ/Clˉa Hill  
parameter (μM) (%) 
1 0.101±0.007 0.020±0.001 1.12±0.10 
2 0.041±0.003 0.008±0.001 1.17±0.14 
3 17.212±1.172 3.442±0.234 1.13±0.10 
 EC50 HCO3ˉ/Clˉb Hill  
parameter (μM) (%) 
1 0.243±0.023 0.048±0.005 1.16±0.15 
2 0.137±0.004 0.027±0.001 1.49±0.07 
3 n.d.c n.d.c n.d. 
avesicles loaded with 489 mM NaCl dispersed in 489 mM NaNO3 
(5 mM phosphate buffer, pH 7.2). bvesicles loaded with 451 mM 
NaCl dispersed in 150 mM Na2SO4 (20 mM phosphate buffer, pH 
7.2) upon addition of a NaHCO3 pulse to make the extravesicular 
bicarbonate concentration 40 mM.cnot determined (carrier load-
ings over 5% promoted less than 50% chloride efflux). 
 
Compounds 1 and 2 were selected as their calculated lipo-
philicity matched the optimal log P range for these compounds 
in order to maximize their transport activity. Compound 3 was 
predicted to display very limited activity. The experimental 
results fully supported this hypothesis. The nature of the ex-
ternal anion impacted dramatically in the rate of chloride 
efflux promoted by these compounds (See supplementary 
Figures S122-S123). Both a Hill parameter close to one and 
the differences in EC50 values found when the chloride efflux 
is measured in the presence of nitrate, bicarbonate or sulfate 
suggested that these compounds function as discrete carriers 
promoting anion exchange through the lipid bilayer. The rela-
tively higher hydrophilicity of bicarbonate compared with 
nitrate resulted in lower chloride efflux at higher carrier load-
ings. This was unsurprising as anion exchange has already 
been reported as the main mechanism accounting for the activ-
ity as anion carriers for tambjamine derivatives. Experiments 
using different metal chlorides such as KCl, RbCl and CsCl 
were also performed and no significant differences were ob-
served (Supplementary Figures S124-S126). Thus influence of 
the metal cation in the transmembrane transport event can be 
ruled out. Carboxyfluorescein leakage assays also rule out the 
possibility of these compounds functioning as membrane 
disruptors promoting unspecific chloride leakage (Supplemen-
tary Figures S136). This set of assays demonstrated that 1 and 
2 are very efficient transmembrane transporters. Compound 3 
represents an adequate control molecule, being structurally 
very similar to 1 and 2 yet displaying significantly lower level 
of transmembrane transport activity (Table 1). 
Anionophores induce intracellular pH changes and cel-
lular toxicity. In order to evaluate the ability of anionophores 
1 - 3 to modulate intracellular pH (pHi), first vital staining 
with acridine orange (AO) was used. When this cell-
permeable dye accumulates in acidic compartments, such as 
lysosomes, it shows a characteristic orange fluorescence emis-
sion, while it emits green fluorescence at higher pH, such as in 
the cytosol. Human lung adenocarcinoma (A549) cells were 
stained with AO and typical granular orange fluorescence was 
observed, corresponding to cellular acidic compartments (Fig-
ure 2a). Treatment with active anion transporters 1 and 2 in-
duced complete loss of orange fluorescence whereas treatment 
with compound 3 did not modify AO emission, compared to 
non-treated cells. These results evidenced an increase in the 
pH of acidic organelles upon treatment with the active anion 
transporters 1 and 2, as opposite to control compound 3. 
We were also interested in studying variations in cyto-
plasmic pH levels. This parameter has been claimed to modu-
late cell proliferation and apoptosis.26 Therefore it could be 
more relevant to gain insight into the mechanisms accounting 
for the cytotoxicity of these compounds. Thus, changes in pHi 
of A549 cells after treatment with 1 - 3 were quantified using 
the pH-sensitive fluorescent dye SNARF®-1. In its ester form, 
5-(and-6)-carboxy seminaphthorhodafluor-1-
acetoxymethylester (SNARF-1-AM) can diffuse across the 
cellular membrane into the cytoplasm. Hydrolization of this 
compound by cellular esterases yield the cell-impermeable 
fluorescent dye carboxy-SNARF-1. This dye can be used for 
quantitative determinations of pHi because it exhibits a signif-
icant pH-dependent emission shift in the appropriate range. 
First, fluorescent signal ratios at 576 nm and 664 nm were 
determined under different pH conditions, which allowed us 
constructing a calibration curve. Then, fluorescence of 
SNARF-1 was measured in A549 cells. Upon treatment with 
10 µM concentration of active anionophores 1 and 2, pHi 
dropped significantly. A lowering of 0.33 ± 0.10 and 0.70 ± 
0.22 pH units was measured for compound 1 and 2 respective-
ly after 1 h (Figure 2b). Such change of pHi is known to be 
sufficient to trigger apoptotic processes in cells.26 Under these 
conditions, compound 3 only induced minor changes of pHi 
inducing an increase of 0.02 ± 0.14 pH units. These results are 
in agreement with the involvement of the transmembrane 
transport activity in the lowering of pHi observed. 
To assess whether chloride transport participated in the cy-
totoxic effect exhibited by 1 and 2, cell viability was measured 
in A549 cells resuspended in Hank’s balanced salt solution 
(HBSS) either containing chloride or without this anion (Fig-
ure 2c, 2d). Moderate yet significant differences between cell 
viability in both buffers upon treatment with 1 and 2were 
observed, with reduced cytotoxicity in absence of chloride. 
Under these conditions, calculated inhibitory concentration 50 
(IC50) values in the presence of chloride dropped to 8.8 µM 
and 9.6 µM from the calculated 12.4 µM and 12.11 µM in 
HBSS without chloride for compounds 1 and 2 respectively. 
This result as well as the reduced toxicity of inactive trans-
porter 3 (See supplementary Figure S136) again supported the 
involvement of anion transport in the cytotoxic effect exerted 




Figure 2. Transmembrane anion transport impact intracellular pH (pHi) levels and reduce cell viability. (a) Acridine orange staining on 
human lung adenocarcinoma (A549) cells. From left to right: Untreated (control) cells; cells treated with compound 1; compound 2 and 
compound 3 (10 µM). Disappearance of orange fluorescence due to basification of acidic organelles is evident upon treatment with active 
anionophores. (b) pHi measurements using SNARF-1 staining. A significant decrease in pHi is observed after treatment with 10 µM of 
compound 1 or 2. * p<0.05; ** p<0.01. (c), (d), Cell viability after treatment with compound 1 and 2 in the presence (HBSS) or absence 
(HBSS without Cl–) of chloride ion. Higher cytotoxicity is observed in the presence of chloride ion. * p<0.05; ** p<0.01. 
Membrane potential changes in liposomes and voltage 
changes in single A549 cells. We decided to explore the po-
tential of these compounds to induce changes in the membrane 
polarization. We first explore this possibility in model lipo-
somes. Thus, membrane potential sensitive dye safranin O was 
used. The fluorescence of this compound is affected by chang-
es in membrane potential.27 POPC vesicles containing NaCl 
were suspended in a Na2SO4 solution. As demonstrated using 
chloride selective electrode assays, compounds 1 - 3 are una-
ble to promote sulfate transport (See Figure S119, S120) and 
under these conditions only chloride permeation can occur. 
Addition of active transporters 1 and 2 at 0.1% molar carri-
er:lipid resulted in a marked decrease in safranin O fluores-
cence (Figure 3b). Control experiments using the essentially 
inactive transporter 3 or DMSO resulted in no significant 
change of fluorescence. These results are consistent with a 
decrease of the membrane potential induced by 1 and 2. Like-
wise, little change in safranin O fluorescence was observed 
when these experiments were carried out with no chloride 
electrochemical potential (Figure 3a).  
We next aimed to assess the ability of anion transporters to 
induce voltage changes in A549 cells. A549 cells were trans-
fected with the VSFP2.32 genetically encoded voltage indica-
tor, which permits monitoring membrane voltage changes by 
recording changes in FRET efficacy between a pair of fluores-
cent proteins.28,29 To determine the voltage range within 
VSFP2.32 reports, voltage changes in A549 cells, VSFP2.32 
expressing cells, were patch-clamped, and a voltage ramp 
(from 130 to -170 mV) was applied. A progressive decrease in 
FRET was observed as the cell membrane was hyperpolarized 
to negative voltages from -30 mV and down to -170 mV (Fig-
ure 3c). We next evaluated the effects of compounds 1-3 on 
membrane voltage. The superfusion of transporter 1 induced a 
robust decrease in the FRET signal (Figure 3d). The decrease 
in the FRET signal indicates that treatment with this com-
pound hyperpolarized A549 cells. These cells normally exhibit 
a resting Vm close to 0 mV that upon facilitated influx of 
anions shifts to more negative values. Similar to the trans-
porter 1, transporter 2 also produced a decrease on FRET 
signal (Supplementary Figure S141), although with slightly 
different kinetics. Thus, transporter 1 had a higher magnitude 
of the signal (0.18 ± 0.03 vs 0.15 ± 0.02) and faster τ time 
constant (5.16 ± 0.79 vs 7.65 ± 0.58 s) than transporter 2. 
Finally, we attempted to demonstrate that the critical feature of 
these compounds in order to induce Vm changes was their 
anion transport abilities. Thus transporter 3, possessing much 
reduced potency as transmembrane anion transporter, was then 
assayed in the FRET illumination protocol, in order to monitor 
possible voltage alterations (Figure 3e). This compound in-
duced significantly lower decreases in the FRET signal (0.03 ± 
0.01) than transporter 1 and 2, thus demonstrating again that 
hyperpolarization of the cell membrane was induced as a 
result of the transmembrane transport facilitated by active 
anion transporters. 
Cytotoxicity of anion transporters. The effects of anion 
transporters 1 - 3 on A549 cancer cells as well as cell lines 
derived from primary tumors from two non-small cell lung 
cancer patients (FIS302 and FIS303) were examined. We were 
interested in determine the cytotoxicity against both differenti-




Figure 3. Transmembrane anion transporters induce changes in membrane potential. (a)-(b) changes in safranin O fluorescence. The anion 
carrier (0.1 molar% with respect to phospholipids) was added at t=120 s, after that the experiments were monitored over 600 s. Each trace 
represents the average of three trials. Compound 1 red trace, 2 blue, 3 grey, control DMSO green. (a) Vesicles loaded with NaCl (28.8 mM 
NaCl, and 5 mM phosphate buffer, pH 7.2, ionic strength 40 mM) were immersed in NaCl (28.8 mM NaCl, and 5 mM phosphate buffer, 
pH 7.2, ionic strength 40 mM and Safranin O 0.2 µM). (b) Vesicles loaded with NaCl (28.8 mM NaCl, and 5 mM phosphate buffer, pH 
7.2, ionic strength 40 mM) were immersed in Na2SO4 (9.6 mM Na2SO4, 5 mM phosphate buffer pH 7.2, ionic strength 40 mM and Safra-
nin O 0.2 µM). (c)-(e) FRET changes of the VSFP2.32 voltage biosensor. (c) a voltage ramp (shown in the middle panel, from 130 to -170 
mV), (d), transporter 1 and (e), transporter 3. Shown are the time-resolved changes in mCerulean and Citrine fluorescence emission signals 
in single A549 cells expressing the VSFP 2.32. The emission intensities of mCerulean (blue trace), Citrine (yellow trace) and the ratio 
FCitrine/FmCerulean (red trace) were recorded simultaneously. Traces are representative of five separate experiments.  
adherence or as spheroids and were treated 10 μM concentra-
tions of each of the selected compounds. The results are 
shown in Figure 4. For all cell lines, viability after 24 h was 
significantly diminished in A549, FIS302 and FIS303 sphe-
roids compared with the cells grown in monolayer by com-
pounds 1 (p=0.012, p<0.0001 and p<0.0001, respectively ) and 
2 (p= 0.018, p=0.004 and p<0.0001, respectively). On theother 
hand, treatment with the much less active transporter 3 did not 
significantly affect the viability of the treated cells. For com-
parative purposes doxorubicin, a classic chemotherapeutic 
drug, was also included in this study. These results indicate 
that active anion transporters selectively inhibited CSC viabil-
ity. Similar results were also observed in a variety of other 
lung cancer cells lines (H1650, H1993, PC9) (supplementary 
Figure S137).  
Anion transporters affect expression of cancer stem cell 
(CSC) surface markers. Stemness properties of CSCs have 
been associated with the expression of several cell surface 
markers.30 Thus, the effect of compounds 1 - 3 on the expres-
sion of lung stem cell surface markers of A549 CSCs as well 
as FIS302 and FIS303, two patient-derived CSCs, was as-
sessed by immunofluorescence and flow cytometry. Since cell 
viability in the presence of 10 µM concentrations of com-
pounds 1 and 2 for 24 h is very low, cells were incubated 
with2.5 µM of each compound in order to analyze potential 
alterations of lung stem cell surface markers before cell death. 
 
Figure 4. Cytotoxicity assays on cancer stem cells and adherent 
cells. A549, FIS302 and FIS303 adherent and CSCs. Cells were 
treated with 10 µM of each compound (1, 2 or 3). Doxorubicin 
(10 μM) was used as control. Mean and standard deviations of 




Figure 5. Compounds 1 and 2 affect expression of cancer stem cell surface markers. (a) A549 (b), FIS302 (c), FIS303 CSCs. CSCs were 
treated with 2.5 M compound 1, 2 or 3 for 24 h and the expression of CD326 (EpCAM), CD166 and CD44 was analyzed by flow cytome-
try. The expression of these markers was relativized to those in control cells. Data represent the average of three independent experiments. 
Bars correspond to standard deviations. 
 
Figure 6. Compounds 1 and 2 induce tumor CSCs spheres disaggregation. E-cadherine expression in FIS302 tumor spheres growing in 
suspension assessed by immunofluorescence. Merged projection of both cell nuclei with pattern of DAPI-staining (blue channel) and E-
cadherine staining (red channel). Scale bar is 50 m. (a) untreated control cells. (b) CSCs treated with compound 1. (c) CSCs treated with 
compound 2. (d) CSCs treated with compound 3. 
Incubation of A549 cells with 2.5 µM of 1 and 2 for 24 h 
led to an increase of the epithelial cell adhesion molecule 
CD326(EpCAM) expression by 70%, and downregulation of 
CD166 by 20% compared to control cells treated with DMSO. 
No significant changes were observed in the expression of 
CD44. Compound 3 induced no significant changes in the 
three surface markers studied here compared to control cells 
(Figure 5a). FIS302 patient-derived CSCs treated with com-
pounds 1 and 2 showed a 30% decrease in CD166 and 
CD44expression (Figure 5b). No significant changes were 
observed in the expression of EpCAM, CD44 and CD166 in 
the cells treated with compound 3 (Figure 5b). FIS303 patient-
derived CSCs treated with compound 1 showed a 50% reduc-
tion in CD166 expression. The treatment with compound 2 led 
to a 30% reduction in CD166 expression. Both compounds 1 
and 2 led to a 30 % decrease in CD44 expression (Figure 5c). 
Similarly to FIS302 cells, no significant changes were ob-
served in the expression of EpCAM, CD44 and CD166 in cells 
treated with compound 3 (Figure 5c). Taken together, down-
regulation of CD166 and upregulation of CD326 (EpCAM) 
populations in A549 CSCs, and downregulation of CD166 and 
CD44 populations in FIS302 and FIS303 patient-derived CSC, 
suggest that the CSCs properties of A549, FIS302 and FIS303 
cells are affected by compounds 1 and 2. Further evidences 
came from inmunofluorescence assays (Figure 6). Thus, the 
size of the tumor spheres decreases when treated with com-
pounds 1 and 2 compared to spheres treated with compound 3 
or DMSO, and disaggregation was evident (Figure 6). 
CONCLUSIONS 
In summary, we have studied two highly active transmem-
brane anion transporters 1 and 2 capable of facilitating trans-
membrane transport of chloride and bicarbonate in model 
liposomes. These compounds induce pHi acidification and 
hyperpolarization of cellular membranes. We have shown that 
this combined effect led to loss of stemness characteristics of 
CSCs and selective elimination of this cell population. The 
fact that the structurally related yet poorly effective transporter 
3 did not exert any of these effects led us to conclude that 
facilitated anion transport plays a crucial role in the biological 
action of these compounds. We conclude that small molecule 
anionophores could represent valuable chemotherapeutics for 
the manipulation of CSCs behavior. 
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